{"filings":[{"id":2105882,"accession_number":"0001628280-26-054288","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2026-08-06T20:08:11+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Q2 rev $28.5M (+21% YoY); GAAP net $45.1M incl $42.4M tax benefit; Repligen deal pending Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $28.5M, up 21% YoY from $23.4M; GAAP gross margin 64%.","GAAP net income $45.1M includes $42.4M non-cash tax benefit from valuation allowance release; adjusted net income $4.2M.","Adjusted EBITDA $7.4M (26% of revenue) vs $5.6M (24%) in Q2 2025.","On July 21, 2026, BioLife agreed to be acquired by Repligen for ~$1.5B enterprise value; expected close Q4 2026.","Biopreservation media used in ~250 ongoing commercial CGT clinical trials (>70% market share); embedded in 18 approved therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2026636,"accession_number":"0001628280-26-051964","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2026-08-03T21:15:26+00:00","items":["7.01","9.01"],"status":"ready","headline":"Repligen CEO sends video to BioLife employees; merger expected to close in Q4 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Repligen CEO Olivier Loeillot recorded video message for BioLife employees on August 3, 2026.","Merger still requires regulatory and shareholder approvals; expected close in Q4 2026.","Repligen describes itself as a bioprocessing tools company with ~2,000 employees globally.","BioLife's CryoStor platform supports majority of US cell-based therapy trials.","Until close, BioLife and Repligen will operate as separate independent companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1804959,"accession_number":"0001628280-26-049232","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2026-07-22T21:17:19+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Repligen to acquire BioLife for $1.5B enterprise value, $31.00 per share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Repligen to acquire BioLife for $31.00/share (0.1442 RGEN shares + $11.25 cash); total enterprise value ~$1.5B.","Transaction expected to close in Q4 2026, subject to BioLife stockholder approval and regulatory clearances.","BioLife reports preliminary Q2 revenue growth ~21% YoY; Repligen reports preliminary Q2 revenue growth ~12-13% organic.","Deal expected to be accretive to Repligen's adjusted EPS by at least $0.05 in year one and at least $0.25 in year two.","Termination fee of $59M payable by BioLife under certain circumstances if deal fails."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":815876,"accession_number":"0001628280-26-040048","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2026-06-03T12:03:31+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLife Solutions issues investor presentation for Jefferies conference; no material updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated June 3, 2026, furnished as Exhibit 99.1.","Available on company website and used at Jefferies Global Healthcare Conference.","No new financial guidance, business updates, or key metrics provided in the filing.","Presentation cover cites 'Industry-Leading Solutions for Cell-Based Therapies'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99132,"accession_number":"0001628280-26-032123","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions Q1 revenue up 25% YoY to $27.5M; net income $1.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $27.5M, +25% YoY from $22.1M; GAAP net income $1.2M vs $0.3M in Q1 2025.","Non-GAAP adjusted EBITDA $6.2M (22% of revenue) vs $5.4M (24% of revenue) in Q1 2025.","GAAP EPS $0.02; GAAP gross margin 64% (down from 67% YoY); adjusted gross margin 64% (down from 68%).","Reiterated FY 2026 guidance: revenue $112.5-115.0M, mid-60% gross margin, full-year net income.","Biopreservation media embedded in 17 commercial CGTs and ~250 ongoing U.S. clinical trials (70% share)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":27500000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114975,"accession_number":"0001628280-26-013277","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLife Solutions issues routine investor presentation; no material news disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation released on March 2, 2026, highlights cell-based therapy solutions.","Presentation available at company's investor relations website.","No financial results, guidance changes, or strategic initiatives included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114974,"accession_number":"0001628280-26-012264","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions Q4 2025 rev $24.8M (+20% YoY), GAAP net income $2.1M; guides 2026 rev $112.5-$115M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $24.8M (+20% YoY); full-year revenue $96.2M (+29% YoY).","GAAP net income Q4 $2.1M ($0.04 EPS) vs net loss $1.2M; adjusted EBITDA $6.9M (28% of revenue).","2026 guidance: revenue $112.5M-$115.0M (17-20% growth), full-year GAAP net income expected.","Biopreservation media in 16 approved CGT products; >70% share in Phase III CGT trials.","Divested evo in Oct 2025 for $25.5M cash; cash & securities $120.2M at Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":96214000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114973,"accession_number":"0001628280-26-001767","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions reports preliminary Q4 2025 revenue $24.8M (+20% YoY); FY 2025 revenue $96.2M beats raised guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 continuing ops revenue $24.8M, up 20% from $20.7M in Q4 2024.","FY 2025 revenue $96.2M, up 29% from $74.6M in 2024, exceeding raised guidance of $95-96M.","Q4 revenue excludes ~$1.3M in biopreservation revenue shifted to Q3 at customer request.","CEO notes evo divestiture complete; company now pure-play cell processing with recurring revenue.","Expects 2026 revenue growth and adjusted EBITDA margin expansion; full guidance in Feb."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":96214000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114972,"accession_number":"0001628280-26-001649","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioLife Solutions' Chief Quality and Operations Officer Karen Foster to retire effective March 31, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Karen Foster, Chief Quality and Operations Officer, notified retirement effective March 31, 2026.","Retirement is not due to any disagreement with the company on operations, policies, or practices.","No replacement or interim appointment has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131360,"accession_number":"0001628280-25-052479","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLife Solutions issues investor presentation; no new financial or operational details disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an 8-K to furnish investor presentation dated November 17, 2025.","Presentation available on company website but full content not included in filing.","No specific earnings, guidance, or material events revealed in the 8-K text or provided exhibit excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131359,"accession_number":"0001628280-25-050163","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Q3 total rev $28.1M (+31% YoY); net income $0.6M; raises cell processing guidance to $93-94M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q3 revenue $28.1M (up 31% YoY); Cell Processing revenue $25.4M (up 33% YoY).","GAAP net income $0.6M vs loss $0.5M in Q3 2024; adjusted EBITDA $7.8M (28% of revenue).","Full-year Cell Processing revenue guidance raised to $93-94M (from $91-93M); total rev $95-96M excl. evo.","Completed sale of evo cold chain logistics on Oct 6 for $25.5M cash, streamlining to pure-play cell processing.","Cash and marketable securities $98.4M as of Sep 30; no evo proceeds included."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":77429000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147945,"accession_number":"0000834365-25-000018","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioLife Solutions annual meeting: two directors face >40% withhold votes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees re-elected; Ellingson and Goswami each received >40% withhold votes (19.8M and 17.5M withheld, respectively).","Advisory say-on-pay approved with 38.4M for, 2.06M against, 84k abstain.","Ratification of Grant Thornton as auditor passed with 43.0M for, 11k against.","Total shares outstanding 47.8M, with 43.1M represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147944,"accession_number":"0000834365-25-000014","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions Q2 revenue up 29%; raises FY2025 guidance to $100-103M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $25.4M (+29% YoY); Cell Processing revenue $23.0M (+28% YoY).","GAAP net loss $15.8M includes non-cash $15.5M IPR&D charge from PanTHERA acquisition.","Non-GAAP adjusted net income $0.5M vs. loss of $1.0M a year ago; adjusted EBITDA $6.1M (24% of revenue).","Raises FY2025 Cell Processing revenue guidance to $91-93M; total revenue guidance to $100-103M.","Biopreservation media embedded in 16 approved therapies; over 250 ongoing trials, including 30+ Phase III."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":49362000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166664,"accession_number":"0001628280-25-023798","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions Q1 revenue up 30% YoY to $23.9M; net loss narrows to $0.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cell Processing revenue of $21.6M (+33% YoY), driven by biopreservation media demand from commercial therapies.","GAAP net loss from continuing ops of $0.4M vs. $3.2M loss in Q1 2024; adjusted EBITDA of $5.7M (24% of revenue).","FY 2025 revenue guidance reaffirmed at $95.5M-$99.0M, representing 16%-20% growth over 2024.","Completed acquisition of PanTHERA CryoSolutions on April 4, 2025, adding novel cryopreservation IRI technology.","Cash and marketable securities of $107.6M at quarter end; balance sheet supports organic and inorganic growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":23941000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184082,"accession_number":"0001628280-25-014541","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioLife appoints Cathy Coste to board as director and audit committee chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective March 18, 2025, Catherine Coste appointed to board, replacing Joydeep Goswami as audit committee chair.","Coste brings over 30 years at Deloitte as senior partner and life sciences industry leader.","She will serve until 2025 Annual Meeting and receive standard non-employee director compensation.","Board expanded to seven members; Coste independent under SEC and Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184081,"accession_number":"0001628280-25-009233","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions Q4 revenue $22.7M (+31% YoY); guides 2025 up 16-20%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $22.7M (up 31% YoY); Cell Processing $20.3M (+37% YoY).","GAAP net loss from continuing ops $2.0M vs $7.2M YoY; adjusted EBITDA $4.0M (18% of revenue).","Completed sales of SciSafe and CBS in Nov 2024 for ~$79.1M total cash; cash and marketable securities $109.2M.","2025 revenue guidance $95.5-99.0M (growth 16-20%); Cell Processing $86.5-89.0M (growth 18-21%).","Cumulative 769 FDA Master File cross-references; biopreservation media in 17 approved cell/gene therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184080,"accession_number":"0001628280-25-001252","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions Q4 preliminary revenue $22.7M, +31% YoY; cell processing beats FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 continuing ops revenue $22.7M (+31% YoY); cell processing $20.3M (+37% YoY, +7% sequentially).","FY2024 continuing ops revenue $82.3M (+8% YoY); cell processing $73.5M exceeded raised guidance of $72-73M.","Evo and Thaw platform revenue fell 14% YoY to $8.7M for FY2024; Q4 down 8%.","Company completed divestitures of freezer and biostorage businesses, sharpening focus on CGT market.","CEO cites momentum, fortified balance sheet; full 2024 results and 2025 outlook due in February earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":82254000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200686,"accession_number":"0001628280-24-052235","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioLife Solutions appoints Tony J. Hunt (Repligen Chairman) to board effective Jan 2, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tony J. Hunt, Executive Chairman of Repligen (Nasdaq: RGEN), appointed to BioLife board.","Appointment increases board size to six members; Hunt qualifies as independent under Nasdaq rules.","Hunt previously served as Repligen CEO (2015-2024) and President of Bioproduction at Life Technologies.","He will serve on the Audit Committee and receive standard non-employee director compensation.","Board cites Hunt's bioprocessing expertise to support BioLife's focus on cell and gene therapy tools."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200685,"accession_number":"0001628280-24-048673","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"BioLife Solutions sells CBS unit to Standex for $6.1M, records $2M in stock comp and $1.5M debt repayment","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold Custom Biogenic Systems (CBS) to Standex International for ~$6.1M; transaction closed Nov 14, 2024.","Incurred $2.0M compensation expense from accelerated share vesting for CBS employees; repaid ~$1.5M of CBS debt.","CBS results classified as discontinued operations; pro forma shows revenue reduction of ~$10.2M for 9mo 2024 and ~$13.6M for FY2023.","Pro forma combined with prior SciSafe sale yields continuing ops net income of $6.9M for 9mo 2024 vs historical net loss $32.6M.","Entered transition services agreement with CBS post-closing; two-year non-compete covenant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200684,"accession_number":"0001628280-24-047143","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions Q3 revenue up 30% to $30.6M; raises Cell Processing guidance to $72-73M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $30.6M (+30% YoY); Cell Processing $19.0M (+43% YoY); adjusted EBITDA $6.1M (20% margin).","GAAP net loss from continuing ops $1.7M vs $15.8M YoY; adj. gross margin 54% (up from 44%).","Completed sale of SciSafe biostorage business for $73M cash on Nov 12, 2024.","FY2024 revenue guidance revised to $98-100M; Cell Processing raised to $72-73M (previously $70-71M).","Biostorage guidance cut to $26-27M due to SciSafe divestiture; management expects positive adjusted EBITDA for full year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":85678000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200683,"accession_number":"0001628280-24-046909","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["1.01","2.01","5.03","9.01"],"status":"ready","headline":"BioLife Solutions sells SciSafe for $73M cash; closes Nov 12, 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold all SciSafe shares to Subzero Purchaser Corp. for $73M; repaid $0.9M of SciSafe debt and paid $3.3M to waive earn-out rights.","Entered transition services agreement with SciSafe for up to 6 months post-close.","Amended SVB loan agreement; added $750K non-refundable termination fee upon early loan termination.","Amended bylaws: quorum reduced to one-third voting power; added exclusive forum for derivative/Securities Act claims.","Pro forma shows continuing ops net income of $9.5M for H1 2024 vs. historical loss of $11.4M; net loss per share improved to $(0.22)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216696,"accession_number":"0001628280-24-036343","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K/A","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions corrects Q2 earnings; raises full-year revenue guidance to $99-101M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $28.3M, down 3% YoY but up 6% sequentially; Cell Processing up 11% sequentially.","GAAP net loss from continuing ops $7.1M (incl $4.1M write-off) versus $5.5M loss a year ago.","Non-GAAP adjusted EBITDA $4.8M or 17% of revenue, up from $1.7M or 6% in Q2 2023.","FY 2024 total revenue guidance raised to $99-101M; Cell Processing guidance raised to $70-71M.","8-K/A corrects prior release to reduce stock compensation by $2.1M from discontinued operations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":55107000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216698,"accession_number":"0001628280-24-036163","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Q2 revenue $28.3M (-3% YoY), net loss $7.1M; raises FY24 revenue guidance to $99-101M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $28.3M (-3% YoY, +6% seq); Cell Processing $18.0M (+11% seq).","GAAP net loss from cont. ops $7.1M (incl $4.1M iVexSol write-off) vs $5.5M loss YoY; adj net loss $2.3M.","GAAP gross margin 51% vs 35% YoY; non-GAAP adj gross margin 52% vs 45%.","Adjusted EBITDA $4.8M (17% rev) vs $1.7M (6%) YoY.","Raises FY2024 revenue guidance to $99-101M from $95.5-100M; Cell Processing to $70-71M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":55107000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216697,"accession_number":"0001628280-24-035254","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioLife Solutions stockholders re-elect five directors, approve say-on-pay, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Roderick de Greef, Joydeep Goswami, Amy DuRoss, Rachel Ellingson, and Timothy Moore re-elected as directors.","Advisory vote on named executive officer compensation approved with 32.5M shares for, 5.0M against.","Ratification of Grant Thornton LLP as independent auditor for 2024 approved with 41.6M shares for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236373,"accession_number":"0001628280-24-022218","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Q1 net loss $10.2M; revenue down 16% YoY; divests GCI freezer unit, reaffirms 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $31.7M (-16% YoY); Cell Processing $16.2M (+10% seq), Biostorage $7.1M (+25% YoY), Freezers $8.4M (-35% YoY).","GAAP net loss $10.2M ($0.22 loss per share); adjusted EBITDA -$1.2M; pro forma ex-GCI adj. EBITDA +$3.6M (13% of revenue).","Closed sale of GCI freezer business Apr 17; funded $4.9M cash into GCI and repaid $2.6M debt to facilitate transaction.","Affirms FY24 revenue guidance $95.5M-$100.0M (ex-freezers); expects full-year positive adjusted EBITDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":31727000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236372,"accession_number":"0001628280-24-017460","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"BioLife Solutions sells Global Cooling for $1, incurs ~$7.4M cash outflows","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold Global Cooling for $1.00; provided $4.9M to meet $7M cash closing condition.","Repaid $2.6M of Global Cooling’s term loan and assumed $1.8M in accounts payable.","Pro forma 2023 revenue drops to $107M from $143M; net loss improves from $66.4M to $57.9M.","Recorded $8.3M pro forma loss on sale; $2.5M RIF costs and $4.5M stock acceleration charges.","SVB consented, released liens on Global Cooling assets; $500K termination fee added to loan agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236371,"accession_number":"0001628280-24-016671","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["2.05","8.01","9.01"],"status":"ready","headline":"BioLife Solutions divests Stirling freezer business for $1; cuts 11% of workforce","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold Global Cooling (Stirling) for $1.00; expects to eliminate several million dollars of quarterly cash burn.","Workforce reduction of 47 employees (~11% of full-time); estimated $2.5M charges in Q2 2024.","Removes $7.5M warranty liabilities; $7M cash left in GCI and $2.6M debt repayment.","Expects higher revenue growth, adjusted EBITDA, and gross margin expansion after sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254035,"accession_number":"0001628280-24-007964","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Q4 rev $32.7M (-26% YoY); guides 2024 rev $95.5-100M ex-freezer; adj EBITDA positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP net loss $13.4M ($0.30 loss/share) vs $49.2M loss ($1.15) in Q4 2022.","Cell Processing platform Q4 rev $14.8M, down 27% YoY but up 11% sequentially.","Freezer divestiture underway; expects sale by end of Q1 2024.","2024 revenue guidance $95.5-100.0M (ex-freezer); expects full-year positive adjusted EBITDA.","Biopreservation media embedded in 14 approved CGT therapies as of Feb 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":143271000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254034,"accession_number":"0001628280-24-000776","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Q4 preliminary revenue $32.7M, down 26% YoY; cell processing up 11% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 total preliminary unaudited revenue $32.7M, down 26% vs Q4 2022 ($44.3M).","Cell processing platform revenue $14.8M, down 27% YoY but up 11% sequentially from Q3 2023.","Full-year 2023 revenue $143.3M, down 11% from $161.8M in 2022.","Divestiture of freezer business progressing; expected to close in Q1 2024.","CEO cites 14 approved CGT therapies using BioLife products; 10 more potential by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":143271000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271504,"accession_number":"0001628280-23-038225","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions Q3 revenue falls 18% YoY; net loss widens to $29.1M on $15.5M impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $33.3M, down 18% YoY; ex-COVID revenue down 10%.","GAAP net loss $29.1M ($0.67 EPS) vs $10.3M loss in Q3 2022; includes $15.5M non-cash impairment.","Biostorage and Services ex-COVID revenue grew 50% YoY; cell processing revenue down 26%.","Cash $42.2M at quarter end; raised $10.4M via share sale in October 2023.","FY2023 revenue guidance narrowed to low end of $144-158M; freezer divestiture expected in early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":110538000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271503,"accession_number":"0001628280-23-034923","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"BioLife Solutions names Roderick de Greef CEO; prelim Q3 rev $33.3M, FY23 guidance at low end","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Rice resigns as CEO and Chairman; Roderick de Greef appointed President, CEO, and Chairman effective Oct 19, 2023.","Preliminary Q3 2023 revenue $33.3M: cell processing $13.3M, storage $6.6M, freezers $13.4M.","FY2023 revenue guidance narrowed to low end of $144M-$158M range; expects flat to modest Q4 cell processing growth.","Garrie Richardson, former GM of biostorage and founder of SciSafe, promoted to Chief Revenue Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271502,"accession_number":"0001628280-23-034715","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2023-10-19T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"BioLife Solutions: Casdin Partners ups stake to 19.5% with $10.4M private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 927,165 new shares to Casdin Partners at $11.19/share, raising ~$10.4M.","Casdin Partners' total ownership rises to ~19.5% of outstanding common stock post-placement.","Transaction closed immediately on October 19, 2023; registration statement to be filed within 30 days.","Issuance is below 20% threshold, so no shareholder vote required under Nasdaq listing rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288376,"accession_number":"0001628280-23-031164","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2023-08-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLife Solutions issues investor presentation; no specific financial updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed investor presentation dated August 2023 under Item 7.01 Regulation FD.","Presentation is available on company website; no earnings or operational milestones highlighted.","No material financial or strategic changes mentioned in the limited exhibit provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288375,"accession_number":"0001437749-23-023954","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2023-08-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioLife execs to receive up to 100% of base salary in stock through Dec 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Michael Rice to receive 50% of base salary in vested shares for Aug 14-Dec 31, 2023; 50% in cash.","EVP Aby Mathew to receive 100% of base salary in shares; CFO and COO to receive 30% in shares.","All board members will receive all remaining 2023 cash compensation in fully vested shares.","Compensation reverts to full cash payment on January 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288374,"accession_number":"0001628280-23-028201","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Q2 revenue falls 3% to $39.5M; net loss $0.23/share; cuts FY guidance; plans freezer divest","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 revenue $39.5M, down 3% YoY; cell processing up 22% but freezers down 26%.","GAAP net loss $10.2M ($0.23 EPS); adjusted EBITDA -$1.2M vs +$1.2M a year ago.","FY2023 revenue guidance lowered to $144M-$158M; previous cell processing guidance $89-93M now $65-74M.","Committed to divest Stirling Ultracold and CBS freezer assets by end of 2023; focus on recurring higher-margin products.","Pro forma H1 2023 revenue ex-freezers $51.5M; adj. gross margin 52%; adj. EBITDA margin 16-18%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":77210000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288373,"accession_number":"0001628280-23-025959","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioLife Solutions stockholders re-elect directors, approve executive compensation and 2023 Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected all seven director nominees: Michael Rice, Joydeep Goswami, Joseph Schick, Amy DuRoss, Rachel Ellingson, Roderick de Greef, and Timothy Moore.","Approved non-binding advisory vote on named executive officer compensation: 28,011,724 for, 5,972,831 against.","Ratified appointment of Grant Thornton LLP as independent auditor for FY2023: 38,080,800 votes for.","Approved 2023 Omnibus Performance Incentive Plan: 32,018,463 votes for, 1,961,503 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308858,"accession_number":"0001437749-23-016750","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioLife Solutions amends severance for CFO and SVP; increases to 12 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO Troy Wichterman severance increased from 9 to 12 months base salary plus COBRA.","SVP Karen Foster severance increased from 6 to 12 months base salary plus COBRA.","Double trigger change-in-control severance, effective Jan 3, 2023, included in amendments.","2023 base salaries: Wichterman $472,000, Foster $382,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308857,"accession_number":"0001437749-23-015312","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"BioLife Solutions sets 2023 annual meeting for July 21; new proposal deadline June 6","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting will be held virtually on July 21, 2023, per company's definitive proxy statement.","Stockholder proposals under Rule 14a-8 must be received by June 6, 2023, due to 30+ day date change.","2022 annual meeting was held June 9, 2022; new deadline applies for proposals and director nominations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308856,"accession_number":"0001437749-23-013652","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions Q1 revenue up 4% to $37.7M; net loss widens, explores sale of freezer lines","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $37.7M (+4% YoY); ex-COVID growth 16%; biopreservation media revenue +28%.","GAAP net loss $13.7M (-$0.32/share) vs $7.4M loss in Q1 2022; adjusted EBITDA -$1.9M.","Adjusted gross margin improved to 37% from 32% in Q4 2022; GAAP gross margin 35%.","Exploring strategic alternatives for ULT cryogenic freezer businesses, including potential divestitures.","Affirmed FY2023 revenue guidance $188-$202M (16-25% YoY growth); Q4'24 aspirational targets reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":37703000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327634,"accession_number":"0001437749-23-007615","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLife Solutions holds Analyst Day; presentation contains no new material info beyond prior earnings release","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Analyst Day held on March 23, 2023; corporate presentation posted on company website.","Presentation includes FY2022 unaudited financials previously disclosed in March 16, 2023 earnings release.","No new material financial or operational data provided during the event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327633,"accession_number":"0001437749-23-006923","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions FY2022 revenue $161.8M (+36% YoY); GAAP net loss $139.8M on $110.4M impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2022 revenue $161.8M, up 36% vs 2021; biopreservation media revenue grew 45%.","GAAP net loss $139.8M (includes $110.4M non-cash impairment of Stirling Ultracold intangible assets); adjusted net loss $29.3M.","Adjusted EBITDA positive at $3.6M for full year; Q4 adjusted EBITDA $1.7M.","Reaffirms 2023 revenue guidance of $188M-$202M, 16-25% growth; cell processing platform expected $89-93M (+30-35%).","Cash and short-term investments $64.1M at year-end; Silicon Valley Bank operational with existing credit facilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345335,"accession_number":"0001437749-22-026595","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Q3 revenue $40.7M (+21% YoY); biopreservation media +50%; tightens FY22 guidance to $160-164M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $10.0M ($0.23 loss per share) vs net income of $79K in Q3 2021.","Adjusted EBITDA turned positive at $1.4M versus negative $2.1M in Q3 2021.","Cell Processing platform revenue $18.1M (+57% YoY); Freezer/Thaw Systems $15.3M (-13% YoY).","Cash, equivalents and marketable securities $62.1M; borrowed $20M via term loan in Q3.","FY2022 revenue guidance narrowed to $160-164M from $160-166M; organic growth expected 37-40%."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":117500000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345334,"accession_number":"0001437749-22-023755","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2022-10-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioLife Solutions COO de Greef to retire, appointed to Board; Phillips promoted to SVP Global Ops","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Roderick de Greef, President & COO, to retire from management effective Jan 3, 2023; will join the Board of Directors.","Geraint Phillips promoted to SVP, Global Operations effective Jan 3, 2023; will assume de Greef's responsibilities.","De Greef postponed his prior retirement to lead integration of Global Cooling acquisition and stabilize ULT freezer line.","Phillips' new salary set at $360K/year; severance includes 9-12 months' pay and COBRA premiums."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361789,"accession_number":"0001437749-22-023053","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2022-09-26T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"BioLife Solutions enters up to $40M term loan facility with Silicon Valley Bank","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term loans up to $40M total; $10M conditional on achieving revenue milestones by June 30, 2023.","Interest at greater of 5.75% or Prime plus 0.50% per annum; cap on rate increase of 1% above funding date rate.","Principal repaid in 24 equal monthly installments starting July 1, 2024 (extendable to July 1, 2025); maturity June 1, 2026 (extendable to 2027).","Prepayment penalty 2% in first year, 1% thereafter; final fee of 5.75% of aggregate principal.","Security interest on all assets except intellectual property; subsidiaries SAVSU, Arctic Solutions, SciSafe, Global Cooling, Sexton Biotechnologies are co-borrowers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361788,"accession_number":"0001437749-22-021377","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2022-08-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioLife Solutions appoints Timothy L. Moore to board of directors effective Sept 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Moore brings 30+ years biopharma ops experience; served as EVP Technical Ops at Kite Pharma (Gilead) and head of Genentech biologics ops.","Moore also serves on Cerus Corporation (CERS) board.","Appointed to Compensation Committee and Nominating and Governance Committee.","Board expands to six members; Moore qualifies as independent under Nasdaq rules.","No related-party transactions requiring disclosure; compensation same as other non-employee directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361787,"accession_number":"0001437749-22-019616","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Q2 rev $40.5M (+30% YoY); net loss $72.6M on $69.9M impairment; guides FY22 rev $160-166M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2022 revenue $40.5M, up 30% YoY; organic growth 44%; biopreservation media revenue up 46%.","GAAP net loss $72.6M ($1.71 loss per share) vs net income $7.9M ($0.19 EPS) in Q2 2021; includes $69.9M non-cash impairment charge.","Adjusted EBITDA positive $1.5M in Q2 2022 vs $3.7M in Q2 2021; adjusted gross margin 36% vs 43% prior year.","Full-year 2022 revenue guidance updated to $160M-$166M (34-39% growth) with positive adjusted EBITDA expected.","Cash and marketable securities $46.6M as of June 30, 2022; down $12.9M from March 31 due to working capital and capex."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":76752000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381204,"accession_number":"0001437749-22-015066","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2022-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioLife Solutions stockholders re-elect all directors, approve equity plan increase","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five nominees re-elected: Michael Rice (26.8M for), Joydeep Goswami (26.5M), Joseph Schick (21.9M), Amy DuRoss (26.0M), Rachel Ellingson (26.3M).","Non-binding advisory vote on executive compensation approved with 20.1M for, 7.0M against, 127K abstain.","Ratification of Grant Thornton as independent auditor for FY2022 passed (31.1M for, 10K against, 8K abstain).","Amendment to 2013 Performance Incentive Plan to increase authorized shares by 2M to 8.5M approved (19.1M for, 8.0M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381203,"accession_number":"0001437749-22-011511","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioLife Solutions Q1 revenue $36.2M (+115% YoY); net loss $7.1M vs $1.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS -$0.17 vs -$0.03; adjusted EBITDA -$814K vs +$2.8M a year ago.","Organic revenue growth 45%; biopreservation media revenue up 53%.","Gross margin GAAP 29%, adjusted 33%; improved sequentially from Q4 2021.","FY22 revenue guidance reaffirmed $159.5-$171M (34-44% growth); expects positive adj. EBITDA.","Management & board to accept shares in lieu of cash compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":36220000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381202,"accession_number":"0001437749-22-008498","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2022-04-07T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"BioLife Solutions dismisses BDO, engages Grant Thornton as new auditor; BDO had adverse opinion on internal controls","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed BDO USA as independent auditor; engaged Grant Thornton effective April 6, 2022.","BDO's audit reports on financial statements for FY 2021 and 2020 were unqualified with no disagreements.","BDO's internal control report for FY 2021 had adverse opinion citing material weaknesses (entity-level controls, risk assessment, monitoring, IT).","Material weaknesses previously disclosed in the 2021 10-K; no other reportable events occurred.","Company provided BDO with a copy of the 8-K; BDO's letter is filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399230,"accession_number":"0001437749-22-006760","cik":834365,"company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","form_type":"8-K","filed_at":"2022-03-18T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"BioLife Solutions receives Nasdaq delisting notice for delayed 10-K filing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on March 17, 2022 for failure to timely file 2021 10-K.","Has until May 16, 2022 to submit a plan to regain compliance.","If plan accepted, Nasdaq may grant extension until September 12, 2022.","CFO states Form 10-K expected to be filed no later than March 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1197006683.3541405,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-18T23:59:59+00:00|399230"}